Molecular basis of cardiovascular drug metabolism: Implications for predicting clinically important drug interactions

Circulation

Volumn 101, Issue 14, 2000, Pages 1749-1753

  Abernethy, Darrell R ^a,b   Flockhart, David A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Drugs; Metabolism; Molecular biology

Indexed keywords

AMIODARONE; BARBITURIC ACID DERIVATIVE; CARDIOVASCULAR AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450; DAUNORUBICIN; DIGOXIN; DILTIAZEM; DIPYRIDAMOLE; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; OMEPRAZOLE; PHENYTOIN; PRAVASTATIN; PROPAFENONE; QUINIDINE; RESERPINE; RIFAMPICIN; SPIRONOLACTONE; TACROLIMUS; THEOPHYLLINE; TICLOPIDINE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE; WARFARIN;

ARTICLE; DRUG ANTAGONISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSFORMATION; DRUG TRANSPORT; HUMAN; PRIORITY JOURNAL;

EID: 0034636203     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.14.1749     Document Type: Article

References (53)